News >

Frontline Mantle Cell Lymphoma Treatment Must Involve Personalized Approach

Nichole Tucker
Published: Wednesday, Aug 07, 2019

Dr. Peter Martin

Peter Martin, MD
First-line therapy for patients with mantle cell lymphoma (MCL) must be administered in an individualized approach based on patient and disease characteristics, according to Peter Martin, MD. 

Peer discussions held during the PER Medical Crossfire: Hematologic Malignancies meeting show several controversies in frontline management, including the difference in therapies that should be used in patients who are younger or older. Physicians do agree, however, that younger patients respond better to intensive therapy than older patients and that BTK inhibition should be used as a second-line therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication